- Prev close
- $183.97
- Day range
- $179.70 – $188.60
KLA rose 3.9% in a strong risk-on tape, with the Nasdaq 100 up 2.8%, and the move looks broadly consistent with its high-quality chip-equipment profile rather than a stock-specific break.
KLAC
KLA CORP
As of Sep 21, 2026
67/100
Worth keeping an eye onHealth ScoreWhy it moved
KLA moved +3.9% while the S&P 500 rose +1.6% and the Nasdaq 100 rose +2.8%, so the session was stronger than the market but not wildly disconnected from the semiconductor bid. The cleaner read is sector leadership, not company-specific news: the broad tape was supportive, and the stock’s gain fits the same AI-and-chip optimism that lifted other semiconductor names.
Volatility check
This looks like normal high-beta volatility rather than a fundamental rerating shock. KLA’s beta is 1.45, so moves are typically larger than the market’s, and the business still shows revenue +11.7% YoY (TTM), latest quarter +15.2% YoY, and EPS +20.6% YoY (TTM), with gross margin +61.6%, operating margin +41.8%, and net margin +35.6%. Valuation is not cheap at PE 50.2, forward PE 32.4, and PEG 1.72, so strong growth is already priced in and that can magnify both upside and downside moves; the session looks supportive, but not out of line with a richly valued quality name.
Earnings preview
The next earnings date is not available this period, so I cannot place the stock against a confirmed report window. What the market can still focus on is whether KLA sustains revenue +11.7% YoY (TTM) and latest quarter +15.2% YoY growth, whether EPS keeps running at +20.6% YoY (TTM), and whether margins remain near gross +61.6%, operating +41.8%, and net +35.6%. The provided facts do not include prior post-earnings reaction history, so I won’t infer one.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track KLAC with WhyIHold
Get a plain-English explanation the next time KLA CORP makes a big move — so you know whether it's benign or worth your attention.